SEC I	Form 4
-------	--------

 $\square$ 

Emp. Stock

Buy)

Option (Right to \$7.<mark>0</mark>6

Explanation of Responses:

## FORM 4 UNIT

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
3235-0287							
Estimated average burden							
0.5							

Transaction(s) (Instr. 4)

675,000

12/21/2018

Date

D

Amount or

Number

of Shares

675,000

/s/ Alane P. Barnes, by power of

\*\* Signature of Reporting Person

\$<mark>0</mark>

Expiration Date

12/20/2028

Title

Commo

<u>attorney</u>

Stock

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Stonehouse Jon P				BIO	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
				BCR	BCRX ]							Officer (give title			pecify	
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 12/20/2018					below) below) President & CEO						
(Street) DURHA	M N	IC	27703	4. If Ar	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Ind Line) X	lividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(5	State)	(Zip)									Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			2. Transaction Date (Month/Day/Year	Execution Date,		Code (Instr.			4 and 5) Securities Beneficially Owned Fol		6. Owner Form: Di (D) or In (I) (Instr.	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
					Code V Amount (A) or (D)			Price	Reported Transaction(s) (Instr. 3 and 4)			(	Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)																
		, Transaction Code (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year) Derivative S (Instr. 3 and			es Security	8. Price of Derivative Security (Instr. 5)			0. ovmership orm: birect (D) r Indirect ) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

Date

Exercisable

12/20/2019

(D)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

12/20/2018

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

A

1. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

(A)

675,000<sup>(1)</sup>

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.